A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Astellas Pharma a/s
- Enrollment
- 211
- Locations
- 1
- Primary Endpoint
- Overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide, who have previously undergone treatment with chemotherapy (docetaxel)
Study Overview
Brief Summary
The purpose of this study is to provide real world data on treatment with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients.
The primary purpose is to evaluate overall survival (OS) in mCRPC patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel) (post chemo patients).
This study will also evaluate treatment duration with enzalutamide in patients pre- and post-chemo.
Detailed Description
The data source in this study is a local hospital registry created from a patient follow up of prostate cancer patients.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
enzalutamide (mCRPC pre-chemo)
Patients treated with enzalutamide prior to chemotherapy
Intervention: enzalutamide (Drug)
enzalutamide and chemotherapy (mCRPC post chemo)
Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
Intervention: enzalutamide (Drug)
enzalutamide and chemotherapy (mCRPC post chemo)
Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
Intervention: docetaxel (Drug)
Outcomes
Primary Outcomes
Overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide, who have previously undergone treatment with chemotherapy (docetaxel)
Time Frame: Up to a maximum of four years
Overall survival is defined as time from initiation to death of any cause.
Secondary Outcomes
- Treatment duration of enzalutamide in post chemo mCRPC patients(Up to a maximum of four years)
- Treatment duration of enzalutamide in pre chemo mCRPC patients(Up to a maximum of four years)